IONIS PHARMACEUTICALS INC 4

Director Joseph Klein III of Ionis Pharmaceuticals Inc. exercised 11,518 stock options, sold 11,518 common shares for roughly $0.9 million, and received new option and RSU grants totaling 7,670 shares.

On July 1, 2026, Ionis Pharmaceuticals Inc. director Joseph Klein III exercised 11,518 non-qualified stock options at $39.94 per share and immediately sold 11,518 common shares in two blocks (99 shares at $79.45 and 11,419 shares at a weighted average of $79.0394) under a pre-arranged Rule 10b5-1 trading plan, effectively monetizing the option spread. In connection with the company’s non-employee director compensation policy, he also received a new stock option grant for 5,369 shares at an exercise price of $79.19 and a restricted stock unit award for 2,301 units, both vesting in full on the earlier of the first anniversary of grant or the next annual shareholder meeting. Following these transactions and grants, Klein directly owned 16,277 shares of Ionis common stock, in addition to 200 shares held indirectly by his son, for which he disclaims beneficial ownership; using the prevailing stock sale prices around $79 per share, his direct common stock holdings are worth approximately $1.28 million. The net effect is a largely compensation- and liquidity-driven set of transactions, with sales appearing to be for tax and monetization purposes rather than a directional change in exposure given the concurrent equity awards.

Filing Facts

CIK

874015

Ticker

IONS

Form

4

Source Type

sec

Accession

0000874015-26-000229

Alert Tier

6